S E Waggoner - JoVE Visualize

Showing results (11-20 of 29) with videos related to

Pageof 3

Sort By:

Carcinogenesis|February 13, 2001

Human cervical tissue metabolizes the tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, via alpha-hydroxylation and carbonyl reduction pathwaysB Prokopczyk, N Trushin, J Leszczynska, et al.

Gynecologic Oncology|November 1, 1994

Influence of in utero diethylstilbestrol exposure on the prognosis and biologic behavior of vaginal clear-cell adenocarcinomaS E Waggoner, R Mittendorf, N Biney, et al.

Gynecologic Oncology|June 30, 2000

One versus two intracavitary brachytherapy applications in early-stage cervical cancer patients undergoing definitive radiation therapyJ Rotmensch, P P Connell, D Yamada, et al.

Gynecologic Oncology|March 1, 1996

p53 protein expression and gene analysis in clear cell adenocarcinoma of the vagina and cervixS E Waggoner, S M Anderson, M C Luce, et al.

Gynecologic Oncology|April 1, 1997

Phase II study of 96-hr continuous-infusion etoposide and doxorubicin with bolus cyclophosphamide in refractory epithelial ovarian cancerG F Fleming, S E Waggoner, J Rotmensch, et al.

Annals of Surgical Oncology|October 1, 1998

Bcl-2 protein expression associated with resistance to apoptosis in clear cell adenocarcinomas of the vagina and cervix expressing wild-type p53S E Waggoner, D A Baunoch, S A Anderson, et al.

International Journal of Radiation Oncology, Biology, Physics|December 21, 2000

Intensity-modulated whole pelvic radiation therapy in patients with gynecologic malignanciesJ C Roeske, A Lujan, J Rotmensch, et al.

Gynecologic Oncology|September 5, 2001

Phase I trial of concomitant vinorelbine, paclitaxel, and pelvic irradiation in cervical carcinoma and other advanced pelvic malignanciesA J Mundt, J Rotmensch, S E Waggoner, et al.

Gynecologic Oncology|July 1, 1987

Serum CA 125 and survival of mice inoculated with ovarian carcinoma and treated with antiestrogen, estrogen, or progestinJ A Holt, S E Waggoner, E Y Lee, et al.

International Journal of Radiation Oncology, Biology, Physics|August 3, 2001

Significant pelvic recurrence in high-risk pathologic stage I--IV endometrial carcinoma patients after adjuvant chemotherapy alone: implications for adjuvant radiation therapyA J Mundt, R McBride, J Rotmensch, et al.

Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:

Pageof 3

Carcinogenesis|February 13, 2001

Human cervical tissue metabolizes the tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, via alpha-hydroxylation and carbonyl reduction pathwaysB Prokopczyk, N Trushin, J Leszczynska, et al.

Gynecologic Oncology|November 1, 1994

Influence of in utero diethylstilbestrol exposure on the prognosis and biologic behavior of vaginal clear-cell adenocarcinomaS E Waggoner, R Mittendorf, N Biney, et al.

Gynecologic Oncology|June 30, 2000

One versus two intracavitary brachytherapy applications in early-stage cervical cancer patients undergoing definitive radiation therapyJ Rotmensch, P P Connell, D Yamada, et al.

Gynecologic Oncology|March 1, 1996

p53 protein expression and gene analysis in clear cell adenocarcinoma of the vagina and cervixS E Waggoner, S M Anderson, M C Luce, et al.

Gynecologic Oncology|April 1, 1997

Phase II study of 96-hr continuous-infusion etoposide and doxorubicin with bolus cyclophosphamide in refractory epithelial ovarian cancerG F Fleming, S E Waggoner, J Rotmensch, et al.

Annals of Surgical Oncology|October 1, 1998

Bcl-2 protein expression associated with resistance to apoptosis in clear cell adenocarcinomas of the vagina and cervix expressing wild-type p53S E Waggoner, D A Baunoch, S A Anderson, et al.

International Journal of Radiation Oncology, Biology, Physics|December 21, 2000

Intensity-modulated whole pelvic radiation therapy in patients with gynecologic malignanciesJ C Roeske, A Lujan, J Rotmensch, et al.

Gynecologic Oncology|September 5, 2001

Phase I trial of concomitant vinorelbine, paclitaxel, and pelvic irradiation in cervical carcinoma and other advanced pelvic malignanciesA J Mundt, J Rotmensch, S E Waggoner, et al.

Gynecologic Oncology|July 1, 1987

Serum CA 125 and survival of mice inoculated with ovarian carcinoma and treated with antiestrogen, estrogen, or progestinJ A Holt, S E Waggoner, E Y Lee, et al.

International Journal of Radiation Oncology, Biology, Physics|August 3, 2001

Significant pelvic recurrence in high-risk pathologic stage I--IV endometrial carcinoma patients after adjuvant chemotherapy alone: implications for adjuvant radiation therapyA J Mundt, R McBride, J Rotmensch, et al.

Pageof 3